Page last updated: 2024-10-31

nafamostat and Jaundice

nafamostat has been researched along with Jaundice in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Jaundice: A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Endo, Y1
Oka, T1
Hanasawa, K1
Yoshioka, T1
Tani, T1
Nakane, Y1
Kodama, M1

Other Studies

1 other study available for nafamostat and Jaundice

ArticleYear
Applications of protease inhibitor to hemoperfusion and plasma exchange as a regional anticoagulant.
    Transactions - American Society for Artificial Internal Organs, 1985, Volume: 31

    Topics: Animals; Anticoagulants; Benzamidines; Dogs; Extracorporeal Circulation; Guanidines; Humans; Jaundic

1985